Mallinckrodt affirms enlisting of first patient for ExpressGraft C9T1 Phase 1 Study
Mallinckrodt plc confirmed the enrollment of first patient for the company's Phase 1 study evaluating the safety and tolerance of ExpressGraft C9T1 skin tissue in the treatment of…
Read More...
Read More...